|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US6429221B1
(en)
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
|
PT2177517E
(pt)
*
|
1996-07-24 |
2011-11-10 |
Celgene Corp |
2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa
|
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
DE19703763C1
(de)
*
|
1997-02-01 |
1998-10-01 |
Gruenenthal Gmbh |
Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
|
|
ES2192342T3
(es)
*
|
1997-11-18 |
2003-10-01 |
Celgene Corp |
2-(2,6-dioxo-3-fluoropiperidin-3-il)-isoindolinas sustituidas y su uso para reducir los niveles de tnfalfa.
|
|
US5955476A
(en)
*
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
US20010006973A1
(en)
*
|
1998-03-16 |
2001-07-05 |
Hon-Wah Man |
1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels
|
|
CA2361806C
(en)
|
1999-03-18 |
2012-03-13 |
Celgene Corporation |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
|
DE19917195B4
(de)
*
|
1999-04-16 |
2006-09-28 |
Immatics Biotechnologies Gmbh |
Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
NZ526683A
(en)
*
|
2000-11-30 |
2008-03-28 |
Childrens Medical Center |
Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
|
|
CN1487935A
(zh)
*
|
2000-12-11 |
2004-04-07 |
����ҩƷ��ҵ��ʽ���� |
改良型水溶性药物组合物
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
EP1389203B8
(en)
*
|
2001-02-27 |
2010-03-10 |
The Governement of the United States of America, represented by The Secretary Department of Health and Human services |
Analogs of thalidomide as angiogenesis inhibitors
|
|
NZ531294A
(en)
*
|
2001-08-06 |
2005-11-25 |
Childrens Medical Center |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
|
EP2272513A1
(en)
|
2002-05-17 |
2011-01-12 |
Celgene Corporation |
Pharmaceutical compositions for treating cancer
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US8404717B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
FR2845994B1
(fr)
*
|
2002-10-18 |
2006-05-19 |
Servier Lab |
Nouveaux derives de benzo[e][1,4]oxazino[3,2-g]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
ZA200503240B
(en)
*
|
2002-10-24 |
2007-11-28 |
Gelgene Corp |
Methods of using and compositions comprising immunodulatory compounds for treatment, modification and management of pain
|
|
MXPA05004488A
(es)
*
|
2002-10-31 |
2005-07-26 |
Celgene Corp |
Composicion para el tratamiento de la degeneracion macular.
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
CH696542A5
(de)
*
|
2003-07-09 |
2007-07-31 |
Siegfried Ltd |
Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
|
|
UA83504C2
(en)
*
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
WO2005028436A2
(en)
|
2003-09-17 |
2005-03-31 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Thalidomide analogs as tnf-alpha modulators
|
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
|
US7612096B2
(en)
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
MXPA06010699A
(es)
|
2004-03-22 |
2006-12-15 |
Celgene Corp |
Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel.
|
|
WO2005112928A1
(en)
*
|
2004-05-05 |
2005-12-01 |
Celgene Corporation |
Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
|
|
ES2437592T3
(es)
*
|
2004-09-03 |
2014-01-13 |
Celgene Corporation |
Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
|
|
JP5366544B2
(ja)
|
2005-06-30 |
2013-12-11 |
セルジーン コーポレイション |
４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオン化合物を調製するための方法
|
|
US7928280B2
(en)
|
2005-07-13 |
2011-04-19 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
|
ES2434946T3
(es)
|
2005-08-31 |
2013-12-18 |
Celgene Corporation |
Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
|
|
JP2009507030A
(ja)
|
2005-09-01 |
2009-02-19 |
セルジーン・コーポレーション |
ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用
|
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
|
|
AU2006332680A1
(en)
*
|
2005-12-29 |
2007-07-12 |
Anthrogenesis Corporation |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
|
WO2007106884A2
(en)
|
2006-03-15 |
2007-09-20 |
Theralogics, Inc. |
Methods of treating muscular wasting diseases using nf-kb activation inhibitors
|
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
WO2008021391A1
(en)
|
2006-08-15 |
2008-02-21 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
|
NZ575061A
(en)
*
|
2006-08-30 |
2011-10-28 |
Celgene Corp |
5-substituted isoindoline compounds
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
LT2420498T
(lt)
|
2006-09-26 |
2017-10-25 |
Celgene Corporation |
5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
|
|
EP1923053A1
(en)
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
|
US8071135B2
(en)
|
2006-10-04 |
2011-12-06 |
Anthrogenesis Corporation |
Placental tissue compositions
|
|
AU2007318210B2
(en)
|
2006-10-06 |
2014-02-20 |
Celularity Inc. |
Native (telopeptide) placental collagen compositions
|
|
ES2523925T3
(es)
|
2007-09-26 |
2014-12-02 |
Celgene Corporation |
Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos
|
|
CA2700617C
(en)
|
2007-09-28 |
2018-11-06 |
Celgene Cellular Therapeutics |
Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
|
|
US20090088393A1
(en)
*
|
2007-09-28 |
2009-04-02 |
Zomanex, Llc |
Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
|
|
CN101909609A
(zh)
*
|
2007-11-08 |
2010-12-08 |
细胞基因公司 |
免疫调节化合物在治疗与内皮功能障碍有关的紊乱中的用途
|
|
US7964354B2
(en)
|
2007-12-20 |
2011-06-21 |
Celgene Corporation |
Use of micro-RNA as a biomarker of immunomodulatory drug activity
|
|
AU2009223014A1
(en)
*
|
2008-03-11 |
2009-09-17 |
Dr. Reddy's Laboratories Ltd. |
Preparation of lenalidomide
|
|
WO2009111948A1
(zh)
*
|
2008-03-13 |
2009-09-17 |
天津和美生物技术有限公司 |
3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
|
|
US20110060010A1
(en)
*
|
2008-03-13 |
2011-03-10 |
Tianjin Hemay Bio-Tech Co., Ltd |
Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
|
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
EP2358697B1
(en)
|
2008-10-29 |
2015-10-21 |
Celgene Corporation |
Isoindoline compounds for use in the treatment of cancer.
|
|
ES2444433T3
(es)
*
|
2008-11-14 |
2014-02-25 |
Concert Pharmaceuticals, Inc. |
Derivados de dioxopiperidinil-ftalimida sustituidos
|
|
US9045453B2
(en)
|
2008-11-14 |
2015-06-02 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
DE102008057284A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
|
|
DE102008057335A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Amorphes Lenalidomid
|
|
DE102008057285A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
|
|
US20120053159A1
(en)
|
2009-02-11 |
2012-03-01 |
Muller George W |
Isotopologues of lenalidomide
|
|
WO2010111631A1
(en)
|
2009-03-25 |
2010-09-30 |
Anthrogenesis Corporation |
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
|
AU2010249615B2
(en)
|
2009-05-19 |
2013-07-18 |
Celgene Corporation |
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
|
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
|
CN101580501B
(zh)
*
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
|
AU2010290822A1
(en)
|
2009-09-03 |
2012-03-29 |
Ranbaxy Laboratories Limited |
Process for the preparation of lenalidomide
|
|
WO2011050962A1
(en)
|
2009-10-29 |
2011-05-05 |
Ratiopharm Gmbh |
Acid addition salts of lenalidomide
|
|
CN102127054B
(zh)
*
|
2009-11-02 |
2013-04-03 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
|
CN101696205B
(zh)
|
2009-11-02 |
2011-10-19 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
|
WO2011069608A1
(en)
|
2009-12-09 |
2011-06-16 |
Ratiopharm Gmbh |
S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
|
|
RU2012131164A
(ru)
|
2009-12-22 |
2014-01-27 |
Селджин Корпорейшн |
(метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
|
|
CA2786266A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
|
SG10201501062SA
(en)
|
2010-02-11 |
2015-04-29 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
US9408831B2
(en)
|
2010-04-07 |
2016-08-09 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
|
CN103402980B
(zh)
|
2011-01-10 |
2016-06-29 |
细胞基因公司 |
作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
|
|
RS56770B1
(sr)
|
2011-03-11 |
2018-04-30 |
Celgene Corp |
Čvrste forme 3-(5-amino-2-metil-4-okso-4h-hinazolin-3-il)-piperidin-2,6-diona i njihove farmaceutske smeše i upotrebe
|
|
AU2012236655B2
(en)
|
2011-03-28 |
2016-09-22 |
Deuterx, Llc, |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
|
MX2013012083A
(es)
|
2011-04-18 |
2014-04-16 |
Celgene Corp |
Biomarcadores para el tratamiento de mieloma multiple.
|
|
EP3096142A3
(en)
|
2011-04-29 |
2017-03-08 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
WO2012177678A2
(en)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues of pomalidomide
|
|
EP2765993B1
(en)
|
2011-09-14 |
2020-05-20 |
Amgen (Europe) GmbH |
Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide
|
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
|
HUE050327T2
(hu)
|
2011-12-27 |
2020-11-30 |
Amgen Europe Gmbh |
Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal
|
|
WO2013126394A1
(en)
*
|
2012-02-21 |
2013-08-29 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
CA2875624A1
(en)
|
2012-06-06 |
2013-12-12 |
Bionor Immuno As |
Hiv vaccine
|
|
CA2877736C
(en)
|
2012-06-29 |
2021-12-07 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
|
TR201904785T4
(tr)
|
2012-08-09 |
2019-05-21 |
Celgene Corp |
(S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU.
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
EP2922838B1
(en)
|
2012-10-22 |
2018-03-14 |
Concert Pharmaceuticals Inc. |
Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
FR2999914B1
(fr)
*
|
2012-12-21 |
2015-08-07 |
Oreal |
Utilisation de derives de l'acide imidocarboxylique pour traiter les alterations de la peau liees a l'age ou au photovieillissement
|
|
FR2999915B1
(fr)
*
|
2012-12-21 |
2017-08-11 |
Oreal |
Utilisation de derives de l'acide imidocarboxylique en tant qu'agent apaisant
|
|
WO2014110322A2
(en)
|
2013-01-11 |
2014-07-17 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
CA2935495C
(en)
|
2013-01-14 |
2021-04-20 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
|
AU2014215458A1
(en)
|
2013-02-05 |
2015-08-13 |
Anthrogenesis Corporation |
Natural killer cells from placenta
|
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
CN104072476B
(zh)
*
|
2013-03-27 |
2018-08-21 |
江苏豪森药业集团有限公司 |
泊马度胺晶型及其制备方法和用途
|
|
EP2986318A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
|
|
EP2815749A1
(en)
*
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
|
CN103497174B
(zh)
*
|
2013-07-29 |
2015-10-28 |
杭州派臣医药科技有限公司 |
泊利度胺的制备和精制方法
|
|
CN104557858B
(zh)
*
|
2013-10-29 |
2018-06-01 |
上海医药工业研究院 |
一种泊利度胺的制备方法
|
|
CN107188884A
(zh)
*
|
2013-10-29 |
2017-09-22 |
上海医药工业研究院 |
一种泊利度胺的纯化方法
|
|
ES2806258T3
(es)
|
2013-12-03 |
2021-02-17 |
Acetylon Pharmaceuticals Inc |
Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
|
|
CN104016967A
(zh)
*
|
2014-04-04 |
2014-09-03 |
南京工业大学 |
一种泊利度胺的合成方法
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN119591582A
(zh)
*
|
2014-04-14 |
2025-03-11 |
阿尔维纳斯运营股份有限公司 |
基于酰亚胺的蛋白水解调节剂和相关使用方法
|
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
|
CN109678840B
(zh)
*
|
2014-08-20 |
2023-12-01 |
河北菲尼斯生物技术有限公司 |
泊马度胺的制备方法
|
|
US10034872B2
(en)
|
2014-08-22 |
2018-07-31 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
|
CN105440013B
(zh)
*
|
2014-08-29 |
2018-10-09 |
杭州和泽医药科技有限公司 |
一种泊马度胺的制备方法
|
|
ES2901509T3
(es)
*
|
2014-10-30 |
2022-03-22 |
Kangpu Biopharmaceuticals Ltd |
Derivado de isoindolina, compuesto intermedio, métodos de preparación, composición farmacéutica y uso del mismo
|
|
US10471156B2
(en)
|
2014-12-19 |
2019-11-12 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide
|
|
EP3233059A1
(en)
|
2014-12-19 |
2017-10-25 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide
|
|
CN104447689B
(zh)
*
|
2014-12-22 |
2016-07-20 |
上海迈柏医药科技有限公司 |
来那度胺的晶型及其制备方法
|
|
HK1245791A1
(zh)
|
2015-01-20 |
2018-08-31 |
阿尔维纳斯运营股份有限公司 |
用於雄激素受体的靶向降解的化合物和方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016191178A1
(en)
*
|
2015-05-22 |
2016-12-01 |
Biotheryx, Inc. |
Compounds targeting proteins, compositions, methods, and uses thereof
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
HUE065109T2
(hu)
|
2015-06-26 |
2024-05-28 |
Celgene Corp |
Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
EP3393457A1
(en)
|
2015-12-22 |
2018-10-31 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
|
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
LT3660004T
(lt)
|
2016-10-11 |
2023-06-12 |
Arvinas Operations, Inc. |
Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai
|
|
EP3535265A4
(en)
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
WO2018102725A1
(en)
|
2016-12-01 |
2018-06-07 |
Arvinas, Inc. |
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
|
|
US20190358262A1
(en)
|
2016-12-03 |
2019-11-28 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
|
US10933059B2
(en)
|
2016-12-16 |
2021-03-02 |
Kangpu Biopharmaceuticals. Ltd. |
Combination, application thereof and treatment method
|
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
RU2019121527A
(ru)
|
2016-12-23 |
2021-01-15 |
Эрвинэс Оперейшнс, Инк. |
Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
|
|
EP3558994A4
(en)
|
2016-12-23 |
2021-05-12 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
MX2019008934A
(es)
|
2017-01-26 |
2019-11-05 |
Arvinas Operations Inc |
Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
|
|
EP3577109A4
(en)
|
2017-01-31 |
2020-11-18 |
Arvinas Operations, Inc. |
CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
|
|
KR102125661B1
(ko)
|
2017-02-13 |
2020-06-22 |
강푸 바이오파마슈티칼즈 리미티드 |
전립선암 치료용 조합, 약학 조성물 및 치료 방법
|
|
KR20240139092A
(ko)
|
2017-05-01 |
2024-09-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법 및 면역조절 화합물의 조합
|
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
|
EP3644721A1
(en)
|
2017-06-29 |
2020-05-06 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
|
CA3077325A1
(en)
|
2017-09-28 |
2019-04-04 |
Celularity Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
EP3505158A1
(en)
|
2017-12-27 |
2019-07-03 |
KRKA, d.d., Novo mesto |
Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
|
|
US11452722B2
(en)
|
2018-01-11 |
2022-09-27 |
Natco Pharma Limited |
Stable pharmaceutical compositions comprising lenalidomide
|
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
|
WO2019164891A1
(en)
|
2018-02-21 |
2019-08-29 |
Celgene Corporation |
Bcma-binding antibodies and uses thereof
|
|
EP3545949A1
(en)
|
2018-03-29 |
2019-10-02 |
Midas Pharma GmbH |
Oral dosage forms comprising pomalidomide crystalline form a
|
|
CN119569702A
(zh)
|
2018-04-04 |
2025-03-07 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
|
WO2019199132A1
(ko)
|
2018-04-13 |
2019-10-17 |
주식회사 삼양바이오팜 |
다양한 용량의 레날리도마이드의 경구용 정제 조성물
|
|
KR102259798B1
(ko)
|
2018-04-13 |
2021-06-02 |
주식회사 삼양홀딩스 |
붕해가 개선된 레날리도마이드의 경구용 정제 조성물
|
|
JP7581052B2
(ja)
|
2018-04-13 |
2024-11-12 |
サムヤン ホールディングス コーポレイション |
レナリドミドの経口用コーティング錠剤組成物
|
|
KR102286500B1
(ko)
|
2018-04-13 |
2021-08-05 |
주식회사 삼양홀딩스 |
레날리도마이드를 포함하는 경구용 고형제제의 제조방법
|
|
WO2019199134A1
(ko)
|
2018-04-13 |
2019-10-17 |
주식회사 삼양바이오팜 |
레날리도마이드를 포함하는 약제학적 조성물
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
EP3880238A1
(en)
|
2018-11-16 |
2021-09-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
BR112021010354A2
(pt)
|
2018-11-30 |
2021-11-03 |
Juno Therapeutics Inc |
Métodos para o tratamento usando terapia celular adotiva
|
|
US20230045737A1
(en)
*
|
2018-12-05 |
2023-02-09 |
Vividion Therapeutics, Inc. |
Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
|
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
WO2020227183A1
(en)
*
|
2019-05-03 |
2020-11-12 |
Dynamic Biologics Inc. |
Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
|
|
CN110343063A
(zh)
*
|
2019-08-09 |
2019-10-18 |
新乡双鹭药业有限公司 |
一种泊马度胺合成中杂质的制备方法
|
|
ES3061133T3
(en)
|
2019-08-26 |
2026-03-31 |
Arvinas Operations Inc |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
US11535606B2
(en)
|
2019-09-23 |
2022-12-27 |
Accutar Biotechnology Inc. |
Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
|
|
US11420956B2
(en)
|
2019-09-23 |
2022-08-23 |
Accutar Biotechnology Inc. |
Ureas having Androgen Receptor degradation activity and uses thereof
|
|
US12310975B2
(en)
|
2019-10-17 |
2025-05-27 |
Arvinas Operations, Inc. |
Modulators of BCL6 proteolysis and associated methods of use
|
|
KR20220103753A
(ko)
|
2019-11-19 |
2022-07-22 |
브리스톨-마이어스 스큅 컴퍼니 |
헬리오스 단백질의 억제제로서 유용한 화합물
|
|
US20230111853A1
(en)
*
|
2019-12-17 |
2023-04-13 |
Orionis Biosciences, Inc. |
Compounds modulating protein recruitment and/or degradation
|
|
EP4077309A1
(en)
|
2019-12-19 |
2022-10-26 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
EP4135668B1
(en)
|
2020-04-15 |
2024-04-17 |
Tecnimede, Sociedade Técnico-Medicinal, SA |
Solid oral dosage form comprising pomalidomide
|
|
EP4146642A1
(en)
|
2020-05-09 |
2023-03-15 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
|
|
EP4204418A1
(en)
|
2020-08-28 |
2023-07-05 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス， インコーポレイテッド |
イソインドリノン化合物
|
|
PT4320112T
(pt)
|
2021-04-06 |
2025-07-07 |
Bristol Myers Squibb Co |
Compostos de oxoisoindolina substituídos por piridinilo
|
|
CA3214806A1
(en)
|
2021-04-16 |
2022-10-20 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
US20250170115A1
(en)
|
2021-12-31 |
2025-05-29 |
A Fine House S.A. |
Lenalidomide oral solution
|
|
EP4456875B1
(en)
|
2021-12-31 |
2025-10-15 |
a Fine House S.A. |
Oral solution comprising lenalidomide
|
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
WO2025122895A1
(en)
|
2023-12-08 |
2025-06-12 |
Arvinas Operations, Inc. |
Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
|
|
WO2026006247A1
(en)
*
|
2024-06-26 |
2026-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
2-(piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof
|